Details for New Drug Application (NDA): 012141
✉ Email this page to a colleague
NDA 012141 describes CYTOXAN, which is a drug marketed by Baxter Hlthcare and is included in two NDAs. It is available from one supplier. Additional details are available on the CYTOXAN profile page.
The generic ingredient in CYTOXAN is cyclophosphamide. There are nineteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cyclophosphamide profile page.
The generic ingredient in CYTOXAN is cyclophosphamide. There are nineteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cyclophosphamide profile page.
Summary for 012141
| Tradename: | CYTOXAN |
| Applicant: | Baxter Hlthcare |
| Ingredient: | cyclophosphamide |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 012141
Suppliers and Packaging for NDA: 012141
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CYTOXAN | cyclophosphamide | TABLET;ORAL | 012141 | NDA AUTHORIZED GENERIC | Baxter Healthcare Corporation | 10019-982 | 10019-982-01 | 1 BOTTLE in 1 CARTON (10019-982-01) / 100 TABLET in 1 BOTTLE (10019-982-09) |
| CYTOXAN | cyclophosphamide | TABLET;ORAL | 012141 | NDA | Baxter Healthcare Corporation | 10019-984 | 10019-984-01 | 1 BOTTLE in 1 CARTON (10019-984-01) / 100 TABLET in 1 BOTTLE (10019-984-09) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
